Adipotide dosage chart
10 mg Vial
Adipotide is dosed at 250 mcg–1 mg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water (max vial capacity) → ~3.33 mg/mL concentration.
- Starting dose
- 250 mcg once daily; gradual escalation by 250 mcg every 2 weeks as tolerated.
- Easy measuring
- At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.33 mcg on a U‑100 insulin syringe.
- Storage
- Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Dosing schedule
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 250 mcg | 7.5 units (0.08 mL) |
| Weeks 3–4 | 500 mcg | 15 units (0.15 mL) |
| Weeks 5–6 | 750 mcg | 22.5 units (0.23 mL) |
| Weeks 7–8 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
Reconstitution steps
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 2Inject slowly down the vial wall; avoid foaming.
- 3Gently swirl/roll until dissolved (do not shake).
- 4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- Safety consideration: Clinical development was discontinued due to safety concerns including reversible kidney toxicity at higher doses. This protocol is for educational purposes only.
How This Works
Adipotide is a peptidomimetic compound designed to selectively target blood vessels within white adipose tissue by binding to prohibitin‑1 on the vascular endothelium. Once bound, it delivers a pro‑apoptotic sequence that triggers vessel destruction, cutting off the blood supply to fat cells and causing them to undergo apoptosis and be metabolized. Preclinical studies in obese rodents demonstrated approximately 30% body weight reduction, and obese primates showed about 11% weight loss after 4 weeks of treatment. A first‑in‑human Phase 1 trial was initiated in obese cancer patients, but further clinical development was discontinued due to strategic and safety reasons, including reversible renal effects observed at higher doses.
Potential Benefits & Side Effects
Observations from preclinical literature and limited human data.
- Preclinical studies showed notable targeted fat mass reduction (up to 30% body weight in rodents, ~11% in primates over 4 weeks).
- Mechanism specifically targets adipose tissue vasculature, sparing other tissues in preclinical models.
- Safety concerns: Clinical development was discontinued due to safety issues; reversible kidney toxicity was dose‑dependent in preclinical studies.
- Mild injection‑site reactions (redness, swelling) may occur with subcutaneous administration.
- Limited human data: Only Phase 1 trial data available; long‑term safety profile in humans is unknown.
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a balanced, protein‑forward diet tailored to energy needs.
- Combine resistance training and aerobic activity to reinforce metabolic adaptations.
- Prioritize sleep and stress management to support adherence and recovery.
- Monitor kidney function if extending beyond initial 4‑week cycle due to preclinical observations of renal effects.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry fully.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (45° if limited subcutaneous fat, 90° if ample tissue).
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation.
- Wait a moment before withdrawing the needle; apply gentle pressure but do not rub the injection site.
important-note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Adipotide’s clinical development was discontinued due to safety concerns. This information is for research purposes only. Not for human consumption.
Adipotide dosage FAQs
How much bacteriostatic water do you use to reconstitute Adipotide?
Add 3.0 mL bacteriostatic water (max vial capacity) → ~3.33 mg/mL concentration. for a 10 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
What is a typical Adipotide dose?
Starting dose: 250 mcg once daily; gradual escalation by 250 mcg every 2 weeks as tolerated.. Figures are research reference values only.
What does the Adipotide dosing schedule look like?
Weeks 1–2 — 250 mcg — 7.5 units (0.08 mL); Weeks 3–4 — 500 mcg — 15 units (0.15 mL); Weeks 5–6 — 750 mcg — 22.5 units (0.23 mL); Weeks 7–8 — 1000 mcg (1.0 mg) — 30 units (0.30 mL). The full table above lists every step with matching syringe units.
What are the mixing steps for Adipotide?
Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake).
How should reconstituted Adipotide be stored?
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles..
How many insulin syringe units equal a Adipotide dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is Adipotide approved for human use?
No. Adipotide is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.